Immune FDA Approved

Cyclosporine

A fungal cyclic undecapeptide that inhibits calcineurin through cyclophilin, FDA approved since November 14, 1983 as Sandimmune for transplant rejection prophylaxis and later as Neoral, Restasis, Cequa, Verkazia and Vevye for autoimmune and ocular surface disease.

ImmunosuppressantCalcineurin InhibitorTransplantDry EyeFDA Approved

Also referenced as: Ciclosporin, Cyclosporin A, Ciclosporin A, CsA, Sandimmune, Sandimmun, Neoral, Gengraf, Restasis, Cequa, OTX-101, Verkazia, Vevye, CyclASol, Ikervis, Papilock Mini

Public product evidence No certificate records are bound to a tracked Cyclosporine product page A record counts here only when a vendor publishes a certificate against one of its own tracked Cyclosporine product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This compound maps to at least one regulated medical product or label context in the United States.

Research area
Immune / inflammation research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Body systems
Immune · Systemic

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
16

Ciclosporin, Cyclosporin A, Ciclosporin A, CsA, Sandimmune, Sandimmun, Neoral, Gengraf, Restasis, Cequa, OTX-101, Verkazia, Vevye, CyclASol, Ikervis, Papilock Mini

Signal depth
High

FDA label signal · 200 trials · 1000 PubMed results

Established

Cyclosporine is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Cyclosporine has 25 name-matched clinical trials (highest phase: Phase 4) and 1000 PubMed-indexed publications and holds an FDA drug label. 5 trials have posted results. Note: 23 retracted publications in the literature.

⚠ 23 retracted publications FAERS (approved drug): 59,688
Human data
Approved drug
Trial quality
Large RCT
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Cyclosporine?

Cyclosporine (international nonproprietary name ciclosporin; also cyclosporin A or CsA) is a cyclic peptide of 11 amino acids produced as a metabolite by a soil fungus that the US label names Beauveria nivea, that the discovery paper called Trichoderma polysporum, and that later work places in the genus Tolypocladium. It is a peptide, but a non-ribosomal one: seven of its residues are N-methylated, one is D-alanine, one is the unusual C9 amino acid 4-butenyl-4-methyl-threonine, and the ring is assembled by cyclosporin synthetase, a single multienzyme polypeptide of roughly 800 kDa that activates each amino acid as a thioester and N-methylates it (Lawen and Zocher, Journal of Biological Chemistry, 1990;265(19):11355–11360), encoded by a 45.8-kilobase open reading frame (Weber et al., Current Genetics, 1994;26(2):120–125). That N-methylated, lipophilic structure lets cyclosporine behave like a small molecule: orally absorbed, metabolized by cytochrome P450 3A and almost insoluble in water.

Sandoz scientists described cyclosporin A in 1976 as a peptide metabolite with remarkable immunosuppressive activity and characterized its selective antilymphocytic effects (Rüegger et al., Helvetica Chimica Acta, 1976;59(4):1075–1092; Borel et al., Agents and Actions, 1976;6(4):468–475). It was the first selective T-cell immunosuppressant, made routine solid-organ transplantation possible, and remains in use systemically and topically on the ocular surface. It has no research-peptide market footprint.

How it works

  • Binds cyclophilin, a peptidyl-prolyl isomerase. The intracellular receptor for cyclosporine is cyclophilin, an abundant cytosolic protein (Handschumacher et al., Science, 1984;226(4674):544–547) later shown to be identical to the peptidyl-prolyl cis-trans isomerase that catalyzes protein folding (Fischer et al., Nature, 1989;337(6206):476–478; Takahashi et al., Nature, 1989;337(6206):473–475). The immunosuppressive effect comes from the drug–protein complex, not from loss of isomerase activity.
  • The cyclophilin–cyclosporine complex inhibits calcineurin. The complex, like FKBP bound to FK506 (tacrolimus), binds and inhibits calcineurin, the calcium- and calmodulin-dependent phosphatase, whereas neither drug nor binding protein alone does so (Liu et al., Cell, 1991;66(4):807–815).
  • Blocks NFAT translocation and cytokine transcription. Calcineurin dephosphorylates the cytoplasmic subunit of NFAT (nuclear factor of activated T cells), letting it enter the nucleus after T-cell receptor stimulation; cyclosporine and FK506 block that translocation, so transcription of interleukin-2 and other early activation genes stops while AP-1 and NF-kappa B are little affected (Flanagan et al., Nature, 1991;352(6338):803–807).
  • Inhibits the mitochondrial permeability transition pore. Independently of its immune effects, cyclosporine inhibits a calcium-dependent pore in the inner membrane of heart mitochondria (Crompton et al., Biochemical Journal, 1988;255(1):357–360), the rationale for later reperfusion-injury trials. In the kidney, long-term treatment reduced glomerular filtration rate to 51 versus 93 mL/min in cyclosporine- versus azathioprine-treated heart recipients, with tubulointerstitial injury and focal glomerular sclerosis on biopsy and end-stage renal failure in 2 of 32 patients, the substrate of its nephrotoxicity (Myers et al., New England Journal of Medicine, 1984;311(11):699–705).

Research status

First clinical use. Cambridge surgeons treated 34 recipients of 36 cadaveric organ allografts (32 kidneys, 2 pancreases and 2 livers) with cyclosporin A as the initial sole immunosuppressant; 20 patients were steroid-free, one developed lymphoma, and adding other immunosuppressants led to fatal infections and further lymphoma (Calne et al., Lancet, 1979;2(8151):1033–1036).

Pivotal randomized trials. In eight European centers, 232 cadaveric kidney recipients were randomized to cyclosporin or azathioprine and steroids; 1-year graft survival was 72% versus 52%, with poorer renal function on cyclosporin (European Multicentre Trial Group, Lancet, 1983;2(8357):986–989). In Canada, 209 recipients were randomized to cyclosporine or azathioprine, each with prednisone; predicted 1-year graft survival was 80.4% versus 64.0% (P = 0.003) and patient survival 96.6% versus 86.4%, while serum creatinine at 90 days was 2.6 versus 2.0 mg/dL (P = 0.03) and one cyclosporine patient developed lymphoma (Canadian Multicentre Transplant Study Group, New England Journal of Medicine, 1983;309(14):809–815). The FDA approved Sandimmune injection (NDA 050573) and oral solution (NDA 050574) on November 14, 1983, and Sandimmune capsules (NDA 050625) on March 2, 1990.

Neoral. Absorption from the oil-based Sandimmune formulation was erratic, with absolute bioavailability from under 10% in liver recipients to 89% in some renal recipients according to the Neoral label. A microemulsion studied in 18 stable renal recipients raised steady-state peak concentration by 39% and area under the curve by 15% at the same dose, with less variability (Mueller et al., Transplantation, 1994;57(8):1178–1182). Neoral capsules (NDA 050715) and oral solution (NDA 050716) were approved on July 14, 1995; the label states that Neoral has increased bioavailability compared with Sandimmune. Generic modified capsules followed from January 13, 2000.

Autoimmune indications. A six-center trial randomized 144 patients with severe rheumatoid arthritis to oral cyclosporin or placebo for six months and found improvements in active joint count (23%), pain (24%) and function (16%), with rises in creatinine and blood pressure (Tugwell et al., Lancet, 1990;335(8697):1051–1055). In a 16-week trial of 85 patients with severe plaque psoriasis, 36%, 65% and 80% of patients on three ascending dose levels were clear or almost clear at 8 weeks, while glomerular filtration rate fell by a median of 16% in a measured subgroup (Ellis et al., New England Journal of Medicine, 1991;324(5):277–284). Both indications are on the Neoral label.

Comparator and exposure trials. ELITE-Symphony randomized 1,645 kidney recipients to standard-dose cyclosporine or daclizumab induction with low-dose cyclosporine, tacrolimus or sirolimus. Low-dose tacrolimus gave the highest 12-month glomerular filtration rate (65.4 versus 56.7 to 59.4 mL/min) and the lowest acute rejection (12.3% versus 25.8% with standard cyclosporine) (Ekberg et al., New England Journal of Medicine, 2007;357(25):2562–2575). A Nantes trial randomizing 231 kidney recipients to lower or higher trough targets found no difference in graft function or survival at 66 months, more rejection with low exposure (9 versus 1) and fewer cancers (23 versus 37, P < 0.034), two thirds of them skin cancers (Dantal et al., Lancet, 1998;351(9103):623–628).

Ophthalmic formulations. Two identical 6-month trials in 877 patients with moderate to severe dry eye showed that 0.05% and 0.1% emulsions improved corneal staining and Schirmer scores over vehicle (Sall et al., Ophthalmology, 2000;107(4):631–639); Restasis 0.05% (NDA 050790) was approved on December 23, 2002, with the first generic emulsion approved on February 2, 2022. A nanomicellar 0.09% solution (OTX-101) met its primary endpoint in 744 patients, with 16.6% versus 9.2% of eyes gaining 10 mm or more on the Schirmer test (P < 0.001) but no separation in symptoms (Goldberg et al., Ophthalmology, 2019;126(9):1230–1237); Cequa (NDA 210913) was approved on August 14, 2018. VEKTIS randomized 169 children with severe vernal keratoconjunctivitis to a 0.1% cationic emulsion or vehicle and met its composite endpoint (P = 0.007) (Leonardi et al., Ophthalmology, 2019;126(5):671–681); Verkazia received European authorization on July 6, 2018 and FDA approval (NDA 214965) on June 23, 2021. ESSENCE-2 (NCT04523129) randomized 834 participants to a water-free 0.1% solution (CyclASol) or vehicle: corneal staining improved by 4.0 versus 3.6 grades at day 29 (P = 0.03) while dryness did not separate (P = 0.38) (Akpek et al., JAMA Ophthalmology, 2023;141(5):459–466); Vevye (NDA 217469) was approved on May 30, 2023. Abroad, Ikervis 1 mg/mL received European authorization on March 19, 2015 for severe keratitis in dry eye disease, and Papilock Mini 0.1% was approved in Japan on October 11, 2005 for vernal keratoconjunctivitis.

Cardioprotection: a failed translation. A 58-patient pilot in ST-elevation myocardial infarction found that an intravenous bolus before reperfusion reduced creatine kinase release and infarct mass on MRI (median 37 versus 46 g, P = 0.04) (Piot et al., New England Journal of Medicine, 2008;359(5):473–481). The confirmatory CIRCUS trial (NCT01502774) randomized 970 patients and found a 1-year composite of death, heart-failure events or adverse remodeling in 59.0% with cyclosporine versus 58.1% with placebo (odds ratio 1.04, P = 0.77), with no benefit on any component (Cung et al., New England Journal of Medicine, 2015;373(11):1021–1031).

Analog and housekeeping. Voclosporin, a structural analog of cyclosporine, achieved complete renal response in 41% versus 23% of lupus nephritis patients in AURORA 1 (NCT03021499) (Rovin et al., Lancet, 2021;397(10289):2070–2080) and was approved as Lupkynis (NDA 213716) on January 22, 2021; it is a distinct molecule. Sandimmune labeling supplements were approved on March 6, 2026, and the current Sandimmune prescribing information covers the capsules and injection, while NDA 050574 for the oral solution remains listed as a prescription product. As of November 2026, the most recent FDA actions on cyclosporine are generic approvals and labeling supplements rather than new indications.

Common dosage forms

  • Sandimmune injection. 50 mg/mL concentrate in 5 mL ampuls, for intravenous infusion in hospital.
  • Sandimmune capsules and oral solution. Soft gelatin capsules of 25, 50 and 100 mg and an oral solution of 100 mg/mL, the original non-modified formulation.
  • Neoral and modified generics. Neoral soft gelatin capsules of 25 and 100 mg (the 50 mg strength is discontinued) and oral solution of 100 mg/mL in a microemulsion base, with generic “cyclosporine, modified” capsules of 25, 50 and 100 mg and oral solution, including Gengraf capsules of 25 and 100 mg.
  • Ophthalmic emulsions and solutions. Restasis 0.05% emulsion in 0.4 mL single-use vials and a multidose bottle, plus generic 0.05% emulsions; Cequa 0.09% solution in 0.25 mL single-use vials; Verkazia 0.1% emulsion in 0.3 mL single-dose vials; Vevye 0.1% water-free solution in a 2 mL multidose bottle; abroad, Ikervis 1 mg/mL emulsion and Papilock Mini 0.1% solution.

Key considerations

  • Regulatory status. The FDA Approved status reflects the November 14, 1983 approval of Sandimmune (cyclosporine) injection under NDA 050573 and oral solution under NDA 050574 for prophylaxis of organ rejection in kidney, liver and heart transplants. Later approvals added Sandimmune capsules (1990), Neoral (1995) with rheumatoid arthritis and psoriasis indications, and the ophthalmic products Restasis (2002), Cequa (2018), Verkazia (2021) and Vevye (2023), all still listed as prescription products.
  • Nephrotoxicity and hypertension are intrinsic to the mechanism. Reduced glomerular filtration appeared in transplant and autoimmune trials alike, chronic nephropathy can progress to renal failure, and lowering exposure trades less toxicity for more rejection.
  • Malignancy and infection follow immunosuppression. Lymphoma and skin cancer track cumulative systemic exposure. The Restasis label reports blood concentrations below the limit of detection, so systemic exposure from the ophthalmic products is negligible.
  • Formulations are not interchangeable. Neoral and Gengraf are labeled as having greater bioavailability than Sandimmune and as not interchangeable with it without supervision. Systemic use depends on whole-blood concentration monitoring, and cytochrome P450 3A interactions change exposure.
  • Naming and relatives. Ciclosporin (INN), cyclosporine (USAN), cyclosporin A and CsA are one molecule, as are Sandimmune, Neoral, Gengraf, Restasis, Cequa, Verkazia, Vevye, Ikervis and Papilock Mini. Tacrolimus is an unrelated macrolide sharing the calcineurin target, and voclosporin is a modified analog with its own approval; neither is an alias.